These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29525494)

  • 1. Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension.
    Phillips RA; Xu J; Peterson LE; Arnold RM; Diamond JA; Schussheim AE
    J Am Coll Cardiol; 2018 Apr; 71(15):1601-1610. PubMed ID: 29525494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
    Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
    PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious Adverse Events Cluster in Participants Experiencing the Primary Composite Cardiovascular Endpoint: A Post Hoc Analysis of the SPRINT Trial.
    Botchway A; Buhnerkempe MG; Prakash V; Al-Akchar M; Adekola B; Flack JM
    Am J Hypertens; 2020 May; 33(6):528-533. PubMed ID: 31930338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
    JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial).
    Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events.
    Bress AP; Greene T; Derington CG; Shen J; Xu Y; Zhang Y; Ying J; Bellows BK; Cushman WC; Whelton PK; Pajewski NM; Reboussin D; Beddu S; Hess R; Herrick JS; Zhang Z; Kolm P; Yeh RW; Basu S; Weintraub WS; Moran AE;
    J Am Coll Cardiol; 2021 Apr; 77(16):1977-1990. PubMed ID: 33888247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualizing treatment choices in the systolic blood pressure intervention trial.
    Ferreira JP; Gregson J; Duarte K; Gueyffier F; Rossignol P; Zannad F; Pocock S
    J Hypertens; 2018 Feb; 36(2):428-435. PubMed ID: 28858981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
    Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
    Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
    Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
    Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Frequency of Atherosclerotic Cardiovascular and Safety Events With Systolic Blood Pressure <120mm Hg Versus 135-139mm Hg in a Systolic Blood Pressure Intervention Trial Primary Prevention Subgroup.
    Plante TB; Juraschek SP; Miller ER; Appel LJ; Cushman M; Littenberg B
    Am J Cardiol; 2018 Oct; 122(7):1185-1190. PubMed ID: 30115425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cumulative SBP and serious adverse events on efficacy of intensive blood pressure treatment: a randomized clinical trial.
    Rueda-Ochoa OL; Rojas LZ; Ahmad S; van Duijn CM; Ikram MA; Deckers JW; Franco OH; Rizopoulos D; Kavousi M
    J Hypertens; 2019 May; 37(5):1058-1069. PubMed ID: 30444838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of Stratified Medicine for High Blood Pressure Management: A Modeling Study Using NHANES Survey Data.
    Porcher R; Tran VT; Blacher J; Ravaud P
    Hypertension; 2019 Dec; 74(6):1420-1427. PubMed ID: 31679427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Hypertension Management Strategies in SPRINT-Eligible US Adults: A Simulation Study.
    Zhang F; Bryant KB; Moran AE; Zhang Y; Cohen JB; Bress AP; Sheppard JP; King JB; Derington CG; Weintraub WS; Kronish IM; Shea S; Bellows BK
    J Am Heart Assoc; 2024 Jan; 13(2):e032370. PubMed ID: 38214272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. J-shaped relationship between cardiovascular risk and efficacy of intensive blood pressure reduction: A post-hoc analysis of the SPRINT trial.
    Attar A; Nouri F; Borazjani R; Sayadi M
    PLoS One; 2020; 15(10):e0240102. PubMed ID: 33002071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of baseline cardiovascular risk on the outcomes of intensive blood pressure intervention: a post hoc analysis of the China rural hypertension control project.
    Sun G; Wang C; Ye N; Shi C; Ouyang N; Qiao L; Li G; Zhang L; Yu Y; Li Z; Zhou Y; Chen Z; Zhang S; Zhang P; Geng D; Miao W; Liu S; Sun Y
    BMC Med; 2024 Jun; 22(1):258. PubMed ID: 38902731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines.
    Egan BM; Li J; Wagner CS
    Hypertension; 2016 Aug; 68(2):318-23. PubMed ID: 27354422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Sun X; Guo Y; Nie Z; Cheng J; Zhou H; Zhong X; Zhang S; Du Z; Zhuang X; Liao X
    Clin Res Cardiol; 2019 Mar; 108(3):273-281. PubMed ID: 30167807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of intensive blood pressure treatment and non-fatal cardiovascular or serious adverse events in older adults with mortality: mediation analysis in SPRINT.
    Krishnaswami A; Rich MW; Kwak MJ; Goyal P; Forman DE; Damluji AA; Solomon M; Rana JS; Kado DM; Odden MC
    Eur J Prev Cardiol; 2023 Aug; 30(10):996-1004. PubMed ID: 37185634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Blood Pressure Classification in Korean Young Adults According to the 2017 American College of Cardiology/American Heart Association Guidelines With Subsequent Cardiovascular Disease Events.
    Son JS; Choi S; Kim K; Kim SM; Choi D; Lee G; Jeong SM; Park SY; Kim YY; Yun JM; Park SM
    JAMA; 2018 Nov; 320(17):1783-1792. PubMed ID: 30398603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.